Efficacy of Anti-osteoporosis Treatment for Men with Osteoporosis: a Meta-analysis

Overview

Journal J Bone Miner Metab

Specialty Endocrinology

Date 2023 Feb 27

PMID 36847867

Authors

Aimei Dong

Xiuwen Fei

Yucheng Huang

Youyuan Huang

Affiliations

Soon will be listed here.

Abstract

Introduction: Osteoporosis and fracture are important healthcare problems for men worldwide, which are relevant to severe disability and mortality. This meta-analysis aimed to assess the effectiveness of pharmacological therapy in men with osteoporosis, and to provide evidence-based hints for clinical practice.

Materials And Methods: PubMed, Embase, Web of Science were searched from inception to July 31, 2022. Pooled standardized mean difference (SMD) and relative risk (RR) were calculated. Heterogeneity between included studies and publication bias were detected.

Results: Twenty clinical studies were enrolled in this meta-analysis. The pooled SMD for mean percentage differences of change from baseline in lumbar spine BMD between the treatment group and the control group was 4.95 (95% CI 2.48, 7.42, I = 99%, p < 0.0001). For mean percentage differences of change in femoral neck BMD, the overall SMD was 3.08 (95% CI 0.95, 5.20, I = 99%, p = 0.0045). For a change in total hip BMD, the overall SMD was 1.06 (95% CI 0.50, 1.63, I = 82%, p = 0.0002). The overall RR for incident vertebral fractures was 0.50 (95% CI 0.37, 0.68, I = 5%, p = 0.3971). The pooled RR for nonvertebral fractures and clinical fracture were 0.74 (95% CI 0.41, 1.33, I = 28%, p = 0.3139) and 0.81 (95% CI 0.54, 1.21, I = 0%, p = 0.2992).

Conclusion: Findings in this meta-analysis indicate that pharmacological treatment increases lumbar spine, femoral neck, total hip BMD, and decreases incident vertebral fractures in men with osteoporosis.

Citing Articles

Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study.

Keaveny T, Adams A, Orwoll E, Khosla S, Siris E, McClung M J Bone Miner Res. 2024; 39(10):1424-1433.

PMID: 38861422 PMC: 11425693. DOI: 10.1093/jbmr/zjae090.

References

Rinonapoli G, Ruggiero C, Meccariello L, Bisaccia M, Ceccarini P, Caraffa A . Osteoporosis in Men: A Review of an Underestimated Bone Condition. Int J Mol Sci. 2021; 22(4). PMC: 7924179. DOI: 10.3390/ijms22042105. View

Kanis J, McCloskey E, Johansson H, Oden A, Melton 3rd L, Khaltaev N . A reference standard for the description of osteoporosis. Bone. 2008; 42(3):467-75. DOI: 10.1016/j.bone.2007.11.001. View

Bliuc D, Nguyen N, Nguyen T, Eisman J, Center J . Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res. 2013; 28(11):2317-24. DOI: 10.1002/jbmr.1968. View

Johnell O, Kanis J . Epidemiology of osteoporotic fractures. Osteoporos Int. 2004; 16 Suppl 2:S3-7. DOI: 10.1007/s00198-004-1702-6. View

Johnell O, Kanis J . An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006; 17(12):1726-33. DOI: 10.1007/s00198-006-0172-4. View

Brauer C, Coca-Perraillon M, Cutler D, Rosen A . Incidence and mortality of hip fractures in the United States. JAMA. 2009; 302(14):1573-9. PMC: 4410861. DOI: 10.1001/jama.2009.1462. View

Gennari L, Bilezikian J . Osteoporosis in men. Endocrinol Metab Clin North Am. 2007; 36(2):399-419. DOI: 10.1016/j.ecl.2007.03.008. View

Willson T, Nelson S, Newbold J, Nelson R, LaFleur J . The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol. 2015; 7:65-76. PMC: 4295898. DOI: 10.2147/CLEP.S40966. View

Khosla S, Amin S, Orwoll E . Osteoporosis in men. Endocr Rev. 2008; 29(4):441-64. PMC: 2528848. DOI: 10.1210/er.2008-0002. View

10.

Vescini F, Chiodini I, Falchetti A, Palermo A, Salcuni A, Bonadonna S . Management of Osteoporosis in Men: A Narrative Review. Int J Mol Sci. 2021; 22(24). PMC: 8705761. DOI: 10.3390/ijms222413640. View

11.

Gennari L, Bilezikian J . New and developing pharmacotherapy for osteoporosis in men. Expert Opin Pharmacother. 2018; 19(3):253-264. DOI: 10.1080/14656566.2018.1428559. View

12.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

13.

Boonen S, Reginster J, Kaufman J, Lippuner K, Zanchetta J, Langdahl B . Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367(18):1714-23. DOI: 10.1056/NEJMoa1204061. View

14.

Boonen S, Orwoll E, Wenderoth D, Stoner K, Eusebio R, Delmas P . Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2008; 24(4):719-25. DOI: 10.1359/jbmr.081214. View

15.

Smith M, Egerdie B, Toriz N, Feldman R, Tammela T, Saad F . Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009; 361(8):745-55. PMC: 3038121. DOI: 10.1056/NEJMoa0809003. View

16.

Orwoll E, Scheele W, Paul S, Adami S, Syversen U, Diez-Perez A . The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18(1):9-17. DOI: 10.1359/jbmr.2003.18.1.9. View

17.

Kaufman J, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky G . Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2004; 16(5):510-6. DOI: 10.1007/s00198-004-1713-3. View

18.

Lewiecki E, Blicharski T, Goemaere S, Lippuner K, Meisner P, Miller P . A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018; 103(9):3183-3193. DOI: 10.1210/jc.2017-02163. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View

20.

Higgins J, Altman D, Gotzsche P, Juni P, Moher D, Oxman A . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. PMC: 3196245. DOI: 10.1136/bmj.d5928. View